walldiver:
You may have better info, but the CEGE GVAX prostate vaccine Phase 2 study posted at at ASCO 2006 by Drs. Small, Higano and others reported better median survival when actual numbers were compared to the Halabi predictions than the 5,8 months that Dr, Small reported in 10/06 for the 9901 trial, that the Ph3 dosing requires two injections on a biweekly basis for 24 weeks and that all Vital 1 enrollment will be in North America. Considering CEGE's strong connections with Novartis. John Hopkins and Harvard, I imagine they will get help with enrollment and money. Also while Vital 1 doesn't have a crossover prorocol to Taxotere, I believe that the trial is uncontrolled after the vaccine dosing is completed much like the Provenge trials, allowing docs to prescribe Taxotere or other taxane. Also, their April analysis of the antibody and antigen reactivity precipitated by their vaccine was scientifically impressive. DNDN moght have delivered a near knock out blow to CEGE if Provenge had been approved, but some feedback that I have been getting is that they are definitely back in the game.
